11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
39 citations
,
May 2004 in “Clinics in Dermatology” The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
September 2024 in “Journal of the American Academy of Dermatology” Lighter skin types respond better to narrowband UVB therapy for cutaneous T-cell lymphoma than darker skin types.
March 2024 in “International Journal of Cosmetic Science” Dandruff is linked to increased T cells and weakened immune protection in hair follicles.
February 2026 in “Nature Communications” A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.
June 2023 in “Research Square (Research Square)” Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
2 citations
,
May 2024 in “Immunity” Stem cells help control the immune response to improve wound healing.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
Alopecia Areata is treated with drugs and therapies to reduce inflammation and immune response.
2 citations
,
November 2015 in “Journal of Investigative Dermatology” RANKL improves the immune response against herpes simplex virus by enhancing T cell activation and could help develop better treatments or vaccines.
2 citations
,
April 2025 in “Journal of Investigative Dermatology” T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
May 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.
11 citations
,
May 2021 in “Journal of Medical Virology” Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
January 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” A specific enzyme is essential for proper hair follicle stem cell development and healthy skin.
1 citations
,
June 2016 in “FEBS open bio” Fish oil increased cell growth and macrophages in the skin but didn't affect COX-2 expression.
18 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.
July 2026 in “Expert Review of Clinical Immunology” New therapies aim to improve long-term hair regrowth in alopecia areata by targeting immune responses.
ILC1-like cells may contribute to hair loss in alopecia areata.
July 2026 in “British Journal of Dermatology” Soluble CD83 can treat alopecia areata by activating immune cells.
November 2025 in “The Journal of Immunology” BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.
45 citations
,
June 2018 in “Frontiers in immunology” MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.
9 citations
,
March 2022 in “Frontiers in Immunology” Foxp3+ Regulatory T Cells are important for immunity and tolerance, affect hair growth and wound healing, and their dysfunction can contribute to obesity-related diseases and other health issues.